Welcome. If you're a registered user, please log-in. If not, please sign-up.

Drug Induced Liver Injury

Effectivley predict DILI with novel models and testing strategies bridging the gap between pre-clinical and clinical research

Informa Life Sciences’ Drug Induced Liver Injury is the only DILI focused event in Europe bridging the gap between pre-clinical and clinical research. Developed though rigorous research with key academic and industry experts in hepatotoxicity; this programme has been specifically designed to provide you with a tailored package of knowledge to propel your DILI testing strategy to the next level. Attend this innovative event to participate in discussions on up-to-the-minute scientific and technological breakthroughs enabling you to develop the best DILI testing strategy for your AIs.

Brand new topics for 2010:

Be the first to hear feedback from ISEAC on definitions of DILI

Keep abreast of the most innovative thinking in liver biology to understand the potential stumbling blocks for your candidate

Hear brand new testing strategies and tools to predict DILI pre-clinically and avoid investing in DILI causing compounds

Learn about the latest screening assays being developed to prevent the entry and occurance of DILI causing compounds

Understand the objective relationship between signs and symptoms and clinical prediction of DILI

Understand how the regulatory landscape is developing surrounding the use of predictive tests for DILI with key presentations from the FDA, BfArM and the ILI SAFE-T consortium

Homepage speakers

Homepage speakers

John R. Foster AstraZeneca Pharmaceuticals, UK
John R. Foster Senior Principal Pathologist AstraZeneca Pharmaceuticals, UK

Guruprasad Aithal Nottingham Digestive Disease Centre
Guruprasad Aithal NHS Co-Director Nottingham Digestive Disease Centre

Weida Tong National Centre for Toxicological Research, FDA
Weida Tong Director, Centre for Toxicoinformatics National Centre for Toxicological Research, FDA

Kevin Park University of Liverpool, UK
Kevin Park Director, MRC Centre for Drugh Safety Science University of Liverpool, UK

Other key speakers include:

Ann K. Daly PhD, Professor of Pharmacogenetics, Newcastle University, UK
Simone Stahl, Associate Principal Scientist, AstraZeneca, UK
Colin Howes, Associate Research Fellow, Pfizer, UK
Christine M. Hunt, Clinical Safety Systems, GSK, USA
Klaus Olejniczak, Scientific Director, Federal Institute for Drugs and Medical Devices (BfArM), Germany
Michael Merz, Head Safety Networks, Novartis, Switzerland
Christoph Wandel, Safety Science Leader, F. Hoffmann - La Roche Ltd, Switzerland



..

Event Sponsor

..
..

..
..

Media Partners

..
..

..

Dates and Venues

29 Jun 2010 - 30 Jun 2010

Renaissance Zurich Hotel

Poll

Which method holds the most promise for predicting DILI pre-clinically?

 
 



 

Our expert speaker panel is made up of representitives from:

  • AstraZeneca
  • University of Liverpool
  • Pfizer
  • GSK
  • F. Hoffmann La Roche
  • FDA
  • BfArM
  • Novartis
  • Newcastle University
  • Frounhofer Institute
  • Duke University
  • University of Surray
  • MSD

Those who attended last year include:

Safety, Metabolomics, Toxicology, Functional validation, Genomics,
Pharmacology, QT, ECG studies, Cardiac Safety, Drug Safety, DMPK,
ADME, Pre-clinical Safety, Data Management and DILI

AND Specialists/Senior Scientists working in:
Drug Safety and Surveillance, Drug Metabolism, Pharmacokinetics,
Proteomics, Pharmacogenetics, Immunoglogy, Bioinformatics,
Pharmacovigilance, Toxicology, Genetics, Modelling and Simulation,
Clinical & Pre-Clinical Pharmacology, Automated Biotechnology,
Medical Science, Product Safety, Drug Development and Clinical
Research, Regulatory Affairs, Quality Assurance

.

Bookmark & Share This Site


Feeds
rss
Like
Share
twitterfacebooklinkedinemail

Event Sponsor

Event Sponsor

Media Partners

Media Partners
Media Partners

Reviews

"Excellent talks and very interesting topics"
Lab Manager
Orion Corporation
"Small but high quality event"
Delegate 2009
AstraZeneca
"An interesting idea to co-locate with live safety"
Delegate 2009
Statistik
"Good meeting overall, correct pitch for inaugural meeting. I would like to see further DILI conferences"
Delegate 2009
Pfizer
"Diverse and interesting talks"
Delegate 2009
Actellon

Download Latest Information Now

(updated 17 June 2013)


QUICK LINKS

Informa Life Sciences


This site is owned and operated by Informa plc

Informa plc Company number 102786, Registered in Jersey, Registered office address: Lime Grove House, Green Street, St Helier, Jersey, JE1 2ST, Address: Gubelstrasse 11, CH-6300, Zug, Switzerland.

Copyright © 2010 Informa plc

EVENTS BY SECTOR


EVENTS BY TYPE